NKGen Biotech Inc. is a clinical-stage biotechnology company. It focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer cell therapies. NKGen Biotech Inc., formerly known as Graf Acquisition Corp. IV, is based in THE WOODLANDS, Texas.
| Revenue (Most Recent Fiscal Year) | $0.08M |
| Net Income (Most Recent Fiscal Year) | $-82.94M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -307.50% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.02 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.02 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $-2.68 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.45 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 44.95M |
| Free Float | 40.29M |
| Market Capitalization | $13.03M |
| Average Volume (Last 20 Days) | 0.25M |
| Beta (Past 60 Months) | 0.84 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 10.36% |
| Percentage Held By Institutions (Latest 13F Reports) | 76.17% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |